Is SLRN or QYLD a better dividend investment in 2026?

SLRN currently yields 88.11% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: SLRN offers higher current income.

What is the dividend yield difference between SLRN and QYLD?

SLRN has a forward dividend yield of 88.11% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 76.19 percentage points.

Home › Compare › SLRN vs QYLD

SLRN vs QYLD: Dividend Comparison 2026

SLRN yields 88.11% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SLRN wins by $2.34M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SLRN

● Live price

88.11%

Share price

$2.27

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2.37M

Annual income

$731,873.50

Full SLRN calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — SLRN vs QYLD

📍 SLRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SLRN	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SLRN + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SLRN pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRN

Annual income on $10K today (after 15% tax)

$7,488.99/yr

After 10yr DRIP, annual income (after tax)

$622,092.48/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, SLRN beats the other by $617,282.06/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRN + QYLD for your $10,000?

SLRN: 50%QYLD: 50%

100% QYLD50/50100% SLRN

Portfolio after 10yr

$1.20M

Annual income

$368,766.41/yr

Blended yield

30.84%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on SLRN right now

SLRN

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$10.50

+362.6% upside vs current

Range: $6.00 — $15.00

Altman Z

1.6

Piotroski

2/9

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRN buys

QYLD buys

No recent congressional trades found for SLRN or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSLRNQYLD

Forward yield	88.11% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$2.37M	$25.4K ✓
Annual income after 10y	$731,873.50 ✓	$5,659.31
Total dividends collected	$2.08M	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: SLRN vs QYLD ($10,000, DRIP)

Year	SLRN Portfolio	SLRN Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$19,511	$8,810.57	$10,352	$1,192.36	+$9.2K → SLRN
2	$36,942	$16,065.36	$10,830	$1,347.57	+$26.1K → SLRN
3	$67,956	$28,428.44	$11,460	$1,539.07	+$56.5K → SLRN
4	$121,587	$48,874.33	$12,275	$1,777.84	+$109.3K → SLRN
5	$211,824	$81,725.42	$13,323	$2,078.95	+$198.5K → SLRN
6	$359,715	$133,063.84	$14,667	$2,463.34	+$345.0K → SLRN
7	$596,079	$211,183.71	$16,396	$2,960.57	+$579.7K → SLRN
8	$964,860	$327,055.60	$18,631	$3,612.97	+$946.2K → SLRN
9	$1,527,165	$494,764.27	$21,548	$4,482.15	+$1.51M → SLRN
10	$2,365,940	$731,873.50	$25,398	$5,659.31	+$2.34M → SLRN

SLRN vs QYLD: Complete Analysis 2026

SLRN — Stock

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Full SLRN Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this SLRN vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRN vs SCHD SLRN vs JEPI SLRN vs O SLRN vs KO SLRN vs MAIN SLRN vs XYLD SLRN vs JEPQ SLRN vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.